Citations

Mayo Clinic

Clear

1031 citation(s) found for "Xu, Clark".

Volume-Outcome Relationships for Percutaneous Coronary Interventions in the Stent Era
Wu, Chuntao , Walford, Gary, King, Spencer B., Holmes, David R. , Ambrose, John A. , Sharma, Samin, Katz, Stanley, Clark, Luther T. , Jones, Robert H., Hannan, Edward L. , Sharma, Samin

Circulation | August 15, 2005 | Volume: 112 | Issue: 8 | Pages: 1171-1179

10.1161/circulationaha.104.528455 | PMID 16103238 Get It

Background— Most studies that are the basis of recommended volume thresholds for percutaneous coronary interventions (PCIs) predate the routine use of stent placement. Methods and Results— Data from New York’s Percutaneous Coronary Interventions Reporting System in 1998 to 2000 (n=107 713) were used to examine the impact of annual hospital volume and annual operator volume on in-hospital mortality, same-day coronary artery bypass graft (CABG) surgery, and same-stay CABG surgery after adjustment for differences in patients’ severity of illness. For a hospital-volume threshold of 400, the odds ratios for low-volume hospitals versus high-volume hospitals were 1.98 (95% CI, 1.17, 3.35) for in-hospital mortality, 2.07 (95% CI, 1.36, 3.15) for same-day CABG surgery, and 1.51 (95% CI, 1.03, 2.21) for same-stay CABG surgery. For an operator-volume threshold of 75, the odds ratios for low-volume versus high-volume operators were 1.65 (95% CI, 1.05, 2.60) for same-day CABG surgery and 1.55 (95% CI, 1.10, 2.18) for same-stay CABG surgery. Operator volume was not significantly associated with mortality. Also, for hospital volumes below 400 and operator volumes below 75, the respective odds of mortality, same-day CABG surgery, and same-stay CABG surgery were 5.92, 4.02, and 3.92 times the odds for hospital volumes of 400 or higher and operator volumes of 75 or higher. Conclusions— Higher-volume operators and hospitals continue to experience lower risk-adjusted PCI outcome rates.
Cancer Patients' and Patient Advocates' Perspectives on a Novel Information Source: A Qualitative Study of The Art of Oncology, When the Tumor Is Not the Target
Vickers, Kristin S. , Hathaway, Julie, Clark, Matthew M. , Britt, Teresa, Looker, Sherry, Johnson, Phaedra, Loprinzi, Charles L. , Patten, Christi A.

Journal of Clinical Oncology | June 17, 2005 | Volume: 23 | Issue: 18 | Pages: 4013-4020

10.1200/jco.2005.12.029 | PMID 15961756 Get It

Serum free light chain ratio is an independent risk factor for progression in monoclonal gammopathy of undetermined significance
Rajkumar, S. Vincent , Kyle, Robert A. , Therneau, Terry M. , Melton, L. Joseph, Bradwell, A.R. , Clark, Raynell, Plevak, Matthew F., Dispenzieri, Angela , Katzmann, Jerry A., Larson, Dirk R. , Rajkumar, S Vincent , Dispenzieri, Angela

Blood | April 26, 2005 | Volume: 106 | Issue: 3 | Pages: 812-817

10.1182/blood-2005-03-1038 | PMID 15855274 Get It

Abstract We hypothesized that the presence of monoclonal free kappa or lambda immunoglobulin light chains in monoclonal gammopathy of undetermined significance (MGUS), as detected by the serum free light chain (FLC) assay increases the risk of progression to malignancy. Of 1384 patients with MGUS from Southeastern Minnesota seen at the Mayo Clinic from 1960 to 1994, baseline serum samples obtained within 30 days of diagnosis were available in 1148. At a median follow-up of 15 years, malignant progression had occurred in 87 (7.6%) patients. An abnormal FLC ratio (kappa-lambda ratio < 0.26 or > 1.65) was detected in 379 (33%) patients. The risk of progression in patients with an abnormal FLC ratio was significantly higher compared with patients with a normal ratio (hazard ratio, 3.5; 95% confidence interval [CI], 2.3-5.5; P < .001) and was independent of the size and type of the serum monoclonal (M) protein. Patients with an abnormal serum FLC ratio, non–immunoglobulin G (non-IgG) MGUS, and a high serum M protein level (≥ 15 g/L) had a risk of progression at 20 years of 58% (high-risk MGUS) versus 37% with any 2 of these risk factors (high-intermediate risk), 21% with one risk factor (low-intermediate risk), and 5% when none of the risk factors were present (low risk).
Interindividual Variation in Posture Allocation: Possible Role in Human Obesity
Levine, James A. , Lanningham‐Foster, Lorraine, McCrady, Shelly K., Krizan, Alisa C., Olson, Leslie R., Kane, Paul H., Jensen, Michael D. , Clark, Matthew M. , Olson, Leslie

Science | January 27, 2005 | Volume: 307 | Issue: 5709 | Pages: 584-586

10.1126/science.1106561 | PMID 15681386 Get It

Obesity occurs when energy intake exceeds energy expenditure. Humans expend energy through purposeful exercise and through changes in posture and movement that are associated with the routines of daily life [called nonexercise activity thermogenesis (NEAT)]. To examine NEAT's role in obesity, we recruited 10 lean and 10 mildly obese sedentary volunteers and measured their body postures and movements every half-second for 10 days. Obese individuals were seated, on average, 2 hours longer per day than lean individuals. Posture allocation did not change when the obese individuals lost weight or when lean individuals gained weight, suggesting that it is biologically determined. If obese individuals adopted the NEAT-enhanced behaviors of their lean counterparts, they might expend an additional 350 calories (kcal) per day.
Evaluation of the DNA Binding Tendencies of the Transition State Regulator AbrB
Bobay, Benjamin G. , Benson, Linda M., Naylor, Stephen , Feeney, Brett, Goshe, Michael B. , Strauch, Mark A., Thompson, Richele J., Cavanagh, John , Clark, A. Clay

Biochemistry | December 21, 2004 | Volume: 43 | Issue: 51 | Pages: 16106-16118

10.1021/bi048399h | PMID 15610005 Get It

Cerebrospinal Fluid Leakage: Agarose Gel Electrophoresis Detection of β2-Transferrin and Nephelometric Quantification of β-Trace Protein
Sanders, Elizabeth L., Clark, Raynell, Katzmann, Jerry A.

Clinical Chemistry | September 30, 2004 | Volume: 50 | Issue: 12 | Pages: 2401-2403

10.1373/clinchem.2004.040246 | PMID 15459095 Get It

Eosinophil degranulation in the allergic lung of mice primarily occurs in the airway lumen
Simson, Ljubov, Newcombe, Nicole R., Koskinen, Aulikki, Mattes, Joërg , Lee, Nancy A., Lee, James J. , Dent, Lindsay A. , Matthaei, Klaus I., Foster, Paul S. , Clark, Kristopher

Journal of Leukocyte Biology | March 16, 2004 | Volume: 75 | Issue: 6 | Pages: 1001-1009

10.1189/jlb.0803391 | PMID 15020648 Get It

AbstractEosinophil degranulation is thought to play a pivotal role in the pathogenesis of allergic disorders. Although mouse models of allergic disorders have been used extensively to identify the contribution of eosinophils to disease, ultrastructural evidence of active granule disassembly has not been reported. In this investigation, we characterized the degree of eosinophil activation in the bone marrow, blood, lung tissue, and airways lumen [bronchoalveolar lavage fluid (BALF)] of ovalbumin-sensitized and aero-challenged wild-type and interleukin-5 transgenic mice. Degranulation was most prominent in and primarily compartmentalized to the airways lumen. Eosinophils released granule proteins by the process of piecemeal degranulation (PMD). Accordingly, recruitment and activation of eosinophils in the lung correlated with the detection of cell-free eosinophil peroxidase in BALF and with the induction of airways hyper-reactivity. As in previous studies with human eosinophils, degranulation of isolated mouse cells did not occur until after adherence to extracellular matrix. However, higher concentrations of exogenous stimuli appear to be required to trigger adherence and degranulation (piecemeal) of mouse eosinophils when compared with values reported for studies of human eosinophils. Thus, mouse eosinophils undergo PMD during allergic inflammation, and in turn, this process may contribute to pathogenesis. However, the degranulation process in the allergic lung of mice is primarily compartmentalized to the airway lumen. Understanding the mechanism of eosinophil degranulation in the airway lumen may provide important insights into how this process occurs in human respiratory diseases.
Excision vs Mohs Surgery for Basal Cell Carcinoma
Otley, Clark C.

Archives of Facial Plastic Surgery | March 1, 2004 | Volume: 5 | Issue: 2 | Pages: 203-203

10.1001/archfaci.5.2.203 | PMID 12633217 Get It

Tobacco Use Outcomes Among Patients With Lung Cancer Treated for Nicotine Dependence
Cox, Lisa Sanderson , Ebbert, Jon O. , Drews, Amanda A., Croghan, Gary A., Clark, Matthew M. , Wolter, Troy D., Decker, Paul A. , Hurt, R. Douglas , Patten, Christi A. , Decker, Paul A.

Journal of Clinical Oncology | October 1, 2002 | Volume: 20 | Issue: 16 | Pages: 3461-3469

10.1200/jco.2002.10.085 | PMID 12177107 Get It

PURPOSE: There is a current lack of consensus about the effectiveness of nicotine dependence treatment for cancer patients. This retrospective study examined the 6-month tobacco abstinence rate among lung cancer patients treated clinically for nicotine dependence. PATIENTS AND METHODS: A date-of-treatment matched case control design was used to compare lung cancer patients (201 lung cancer patients, 41% female) and nonlung cancer patients (201 controls, 45% female) treated in the Mayo Clinic Nicotine Dependence Center between 1988 and 2000. The intervention involves a brief consultation with a nicotine dependence counselor. A treatment plan individualized to the patient’s needs is then developed. The primary end point was the self-reported, 7-day point prevalence abstinence from tobacco at 6-month follow-up. RESULTS: At baseline, compared with the controls, the lung cancer patients were significantly older (P < .001), reported higher motivation to stop smoking (P = .003), and were at a higher stage of change (P = .002). The 6-month tobacco abstinence rate was 22% for the lung cancer patients compared with 14% of the control patients (P = .024). After adjusting for age, sex, baseline cigarettes smoked per day, and stage of change, no significant difference was detected between lung cancer patients and controls on the tobacco abstinence rate. CONCLUSION: The results suggest that nicotine dependence treatment is effective for patients with a diagnosis of lung cancer. The majority of lung cancer patients were motivated to stop smoking.
Centrosome amplification drives chromosomal instability in breast tumor development
Lingle, Wilma L., Barrett, Susan L., Negron, Vivian , D’Assoro, Antonino B. , Boeneman, Kelly, Whitehead, Clark M., Reynolds, Carol, Salisbury, Jeffrey L., Liu, Wanguo

Proceedings of the National Academy of Sciences | July 26, 2002 | Volume: 99 | Issue: 4 | Pages: 1978-1983

10.1073/pnas.032479999 | PMID 11830638 Get It

Earlier studies of invasive breast tumors have shown that 60–80% are aneuploid and ≈80% exhibit amplified centrosomes. In this study, we investigated the relationship of centrosome amplification with aneuploidy, chromosomal instability, p53 mutation, and loss of differentiation in human breast tumors. Twenty invasive breast tumors and seven normal breast tissues were analyzed by fluorescence in situ hybridization with centromeric probes to chromosomes 3, 7, and 17. We analyzed these tumors for both aneuploidy and unstable karyotypes as determined by chromosomal instability. The results were then tested for correlation with three measures of centrosome amplification: centrosome size, centrosome number, and centrosome microtubule nucleation capacity. Centrosome size and centrosome number both showed a positive, significant, linear correlation with aneuploidy and chromosomal instability. Microtubule nucleation capacity showed no such correlation, but did correlate significantly with loss of tissue differentiation. Centrosome amplification was detected in in situ ductal carcinomas, suggesting that centrosome amplification is an early event in these lesions. Centrosome amplification and chromosomal instability occurred independently of p53 mutation, whereas p53 mutation was associated with a significant increase in centrosome microtubule nucleation capacity. Together, these results demonstrate that independent aspects of centrosome amplification correlate with chromosomal instability and loss of tissue differentiation and may be involved in tumor development and progression. These results further suggest that aspects of centrosome amplification may have clinical diagnostic and/or prognostic value and that the centrosome may be a potential target for cancer therapy.